[{"orgOrder":0,"company":"Nobelpharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"JAPAN","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"Fosphenytoin Sodium","moa":"||Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Nobelpharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Nobelpharma \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Nobelpharma \/ Inapplicable"},{"orgOrder":0,"company":"Sedor Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Fosphenytoin Sodium","moa":"||NaV channel-alpha-subunit","graph1":"Neurology","graph2":"Approved FDF","graph3":"Sedor Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Sedor Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Sedor Pharmaceuticals \/ Inapplicable"}]

Find Clinical Drug Pipeline Developments & Deals for Fosphenytoin

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          EPSC
                          Not Confirmed
                          EPSC
                          Not Confirmed

                          Details : Undisclosed

                          Product Name : Undisclosed

                          Product Type : Undisclosed

                          Upfront Cash : Inapplicable

                          July 29, 2022

                          Lead Product(s) : Fosphenytoin Sodium,Inapplicable

                          Therapeutic Area : Infections and Infectious Diseases

                          Highest Development Status : Phase III

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          02

                          EPSC
                          Not Confirmed
                          EPSC
                          Not Confirmed

                          Details : Ready-to-dilute and room temperature stable, SESQUIENT is the only FDA-approved fosphenytoin that allows point-of-care storage, as well as fast and efficient administration in emergency rooms and intensive care units.

                          Product Name : Sesquient

                          Product Type : Other Small Molecule

                          Upfront Cash : Inapplicable

                          August 11, 2020

                          Lead Product(s) : Fosphenytoin Sodium,Inapplicable

                          Therapeutic Area : Neurology

                          Highest Development Status : Approved FDF

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          03

                          EPSC
                          Not Confirmed
                          EPSC
                          Not Confirmed

                          Details : Undisclosed

                          Product Name : Undisclosed

                          Product Type : Undisclosed

                          Upfront Cash : Inapplicable

                          October 25, 2019

                          Lead Product(s) : Fosphenytoin Sodium,Inapplicable

                          Therapeutic Area : Infections and Infectious Diseases

                          Highest Development Status : Phase II

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          04

                          EPSC
                          Not Confirmed
                          EPSC
                          Not Confirmed

                          Details : Undisclosed

                          Product Name : Undisclosed

                          Product Type : Undisclosed

                          Upfront Cash : Inapplicable

                          December 12, 2018

                          Lead Product(s) : Fosphenytoin Sodium,Inapplicable

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase II

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          05

                          Aatif Husain

                          Country arrow
                          EPSC
                          Not Confirmed

                          Aatif Husain

                          Country arrow
                          EPSC
                          Not Confirmed

                          Details : Undisclosed

                          Product Name : Undisclosed

                          Product Type : Other Small Molecule

                          Upfront Cash : Inapplicable

                          October 25, 2011

                          Lead Product(s) : Fosphenytoin Sodium,Lacosamide

                          Therapeutic Area : Neurology

                          Highest Development Status : Phase II

                          Sponsor : UCB Pharma S.A

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank